Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction
NCT ID: NCT07153744
Last Updated: 2025-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
9588 participants
INTERVENTIONAL
2025-09-01
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection Fraction
NCT05583773
A Trial of SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure
NCT07230145
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
NCT04912518
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
NCT05135871
Pirfenidone Treat Myocardial Fibrosis After Acute Myocardial Infarction
NCT05531955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Patients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
Patients in the conventional treatment group will receive standard treatment in accordance with guidelines and consensuses after surgery, and this will last for 12 months.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
the Shexiang Baoxin Pill Group
Patients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
Shexiang Baoxin Pill
Patients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
the Conventional Treatment Group
Patients in the conventional treatment group will receive standard treatment in accordance with guidelines and consensuses after surgery, and this will last for 12 months.
Aspirin
Patients in the Shexiang Baoxin Pill(MUSKARDI) group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aspirin
Patients in the Shexiang Baoxin Pill(MUSKARDI) group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
Shexiang Baoxin Pill
Patients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In accordance with the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes , meeting the diagnostic criteria for acute myocardial infarction, including typical chest pain lasting for ≥20 minutes, electrocardiographic manifestations of ST-segment elevation (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), and serum high-sensitivity troponin (hs-cTn) levels exceeding the 99th percentile of the upper reference limit at least once with dynamic changes
* Presenting for treatment within \<24 hours of symptom onset and scheduled to undergo PCI
* The patient or their guardian has signed the informed consent form
Exclusion Criteria
* Being allergic to Shexiang Baoxin Pills, unable to tolerate them, or having other conditions that prevent completion of the trial drug administration
* Being pregnant, planning to become pregnant, or breastfeeding women
* Having participated in other clinical studies within 3 months
* Being deemed unsuitable for inclusion in this study by the researcher
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Huashan Hospital
OTHER
Shanghai 10th People's Hospital
OTHER
Shanghai 6th People's Hospital
OTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Shanghai East Hospital
OTHER
Longhua Hospital
OTHER
Second Affiliated Hospital of Soochow University
OTHER
Affiliated Hospital of Jiangsu University
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
The First People's Hospital of Lianyungang
OTHER
Huai'an First People's Hospital
OTHER
Sir Run Run Shaw Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
First Affiliated Hospital of Ningbo University
NETWORK
Shandong Provincial Hospital
OTHER_GOV
Qianfoshan Hospital
OTHER
Weihai Municipal Hospital
OTHER
Weifang People's Hospital
OTHER
Rizhao People's Hospital
OTHER
The Affiliated Hospital of Qingdao University
OTHER
Jining First People's Hospital
OTHER
Linyi People's Hospital
OTHER
Xiangya Hospital of Central South University
OTHER
Second Xiangya Hospital of Central South University
OTHER
Yueyang Central Hospital
OTHER
The First Affiliated Hospital of University of South China
OTHER
The Central Hospital of Shaoyang
UNKNOWN
The First People's Hospital of Changde City
OTHER
Wuxi People's Hospital
OTHER
Jinhua Central Hospital
OTHER
The Third Affiliated Hospital of Wenzhou Medical University
OTHER
Shuguang Hospital of Shanghai University of Traditional Chinese Medicine
UNKNOWN
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
OTHER
ZhuZhou Central Hospital
OTHER
First People's Hospital of Chenzhou
OTHER
People's Hospital of Quzhou
OTHER
Xuzhou New Health Hospital
UNKNOWN
Taizhou Enze Medical Center Group
OTHER
Beijing Chao Yang Hospital
OTHER
Civil Aviation General Hospital
OTHER
Xuanwu Hospital, Beijing
OTHER
Beijing Friendship Hospital
OTHER
Peking University People's Hospital
OTHER
Beijing Electric Power Hospital
OTHER
Renmin Hospital of Wuhan University
OTHER
Wuhan No.1 Hospital
OTHER
Jingzhou Central Hospital
OTHER
The First Affiliated Hospital of Dalian Medical University
OTHER
Ansteel Group General Hospital
UNKNOWN
General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group
UNKNOWN
The First Affiliated Hospital of Zhengzhou University
OTHER
Huaihe Hospital of Henan University
OTHER
Zhoukou Central Hospital
OTHER
The First Affiliated Hospital of Henan University of Science and Technology
OTHER
First Affiliated Hospital of Nanyang Medical College
OTHER
Jiaozuo Second People's Hospital
UNKNOWN
Anyang Area Hospital of Puyang City
UNKNOWN
Shijiazhuang People's Hospital
OTHER
Cangzhou Central Hospital
OTHER
The First Hospital of Hebei Medical University
OTHER
Handan Central Hospital
OTHER
The People's Hospital of Langfang City
UNKNOWN
Xingtai Central Hospital
UNKNOWN
North China University of Science and Technology
OTHER
The First Affiliated Hospital of Anhui Medical University
OTHER
the First Hospital of Anhui University of Science and Technology
UNKNOWN
Chaohu Hospital of Anhui Medical University
OTHER
Tongling People's Hospital
OTHER_GOV
Huang Shan People's Hospital
OTHER
Huaibei Miners General Hospital
UNKNOWN
The Second Affiliated Hospital of Fujian Medical University
OTHER
Changzhi Medical College
OTHER
LinFen People's Hospital
UNKNOWN
Shanxi Cardiovascular Hospital
OTHER
Dazhou First People's Hospital
UNKNOWN
The Affiliated Hospital Of Southwest Medical University
OTHER
The Third Affiliated Hospital of Guangzhou Medical University
OTHER
The First Affiliated Hospital of Guangdong Pharmaceutical University
OTHER
Yangchun People's Hospital
UNKNOWN
Shaoguan People's Hospital
UNKNOWN
Guilin People's Hospital
UNKNOWN
The First Affiliated Hospital of Nanchang University
OTHER
Ji'an Central People's Hospital
UNKNOWN
Jiangxi Provincial People's Hopital
OTHER
People's Hospital of Chongqing
OTHER
Ankang Central Hospital
OTHER
Xiangyang Central Hospital
OTHER
Tianjin Third Central Hospital
OTHER
General Hospital of Ningxia Medical University
OTHER
The Second Affiliated Hospital of Hainan Medical University
OTHER
Lanzhou University Second Hospital
OTHER
Jilin Province People's Hospital
UNKNOWN
Inner Mongolia Autonomous Region People's Hospital
UNKNOWN
Yan'an Hospital of Kunming City
UNKNOWN
The People's Hospital of Jizhou District, Tianjin
UNKNOWN
The Southwest Hospital of Army Medical University
UNKNOWN
The First People's Hospital of Nanning
UNKNOWN
The People' s Hospital of Jiangmen
UNKNOWN
The second People's Hospital of Guiyang
UNKNOWN
The Third People's Hospital of Chengdu
OTHER
The Tirst People's Hospital of Mianyang
UNKNOWN
First Affiliated Hospital of Fujian Medical University
OTHER
The First People's Hospital of Chu Zhou
UNKNOWN
Xuancheng people's hospital
UNKNOWN
Shanghai Hutchison Pharmaceuticals Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Hospital, Fudan University
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jing min Zhou, doctorate in medicine
Role: backup
Related Links
Access external resources that provide additional context or updates about the study.
National Universal Health Security Information Platform - Medical Research Registration and Filing Information System
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HMPE202501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.